SCHEMBL19783903

SCHEMBL19783903

CC[C@@H](NC(=O)c1cn(-c2ncc(F)cc2Cl)c2nc(Cl)ccc2c1=O)C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
PDE4A P27815 4/20 0.34
KMT2A Q03164 4/20 0.34
KCNH2 Q12809 3/20 0.34
MEN1 O00255 2/20 0.34
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34
MALT1 Q9UDY8 2/20 0.33
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CNR1 P21554 1/20 0.31
CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19783905 1.00 GSK3B (0.35) GSK3BDYRK1APDE4AKMT2AKCNH2
SCHEMBL19784014 0.93 GSK3B (0.35) GSK3BDYRK1APDE4AKMT2AKCNH2
SCHEMBL20969353 0.93 GSK3B (0.35) GSK3BDYRK1APDE4AKMT2AKCNH2
SCHEMBL19784013 0.93 GSK3B (0.35) GSK3BDYRK1APDE4AKMT2AKCNH2
SCHEMBL20532056 0.88 KMT2A (0.35) GSK3BDYRK1APDE4AKMT2AKCNH2
SCHEMBL18313527 0.88 KMT2A (0.35) GSK3BDYRK1APDE4AKMT2AKCNH2
SCHEMBL20532047 0.88 KMT2A (0.35) GSK3BDYRK1APDE4AKMT2AKCNH2
SCHEMBL20969339 0.87 KMT2A (0.33) GSK3BPDE4AKMT2AKCNH2MEN1
SCHEMBL19783902 0.87 KMT2A (0.33) GSK3BPDE4AKMT2AKCNH2MEN1
SCHEMBL19784024 0.86 PDE4A (0.42) PDE4AKMT2AKCNH2MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3481823-B1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF Bayer Pharma AG (DE) 2020-10-28 EP disclosed
US-20190241562-A1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-08-08 US disclosed
US-20190241562-A1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-08-08 US disclosed
EP-3481823-A1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF Bayer Pharma Aktiengesellschaft (DE) 2019-05-15 EP disclosed
WO-2018011017-A1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241562-A1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF GLS, TNNI3, AADAC GSK3B 3455/4885DYRK1A 2447/4885PDE4A 793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.